drugset / Trial / NCT04978428

Epidiolex in Obsessive Compulsive Disorder and Related Disorders

NCT04978428 ↗

Phase 2 Completed 4 enrolled University of Chicago
NaSingle-groupOpen-labelTreatment

Summary

The primary objective of the proposed study is to evaluate the safety and efficacy of Epidiolex (cannabidiol) in adults with obsessive compulsive and related disorders (OCRDs). Subjects will be treated in an open-label fashion with Epidiolex for two weeks.

Timeline

Start
2022-04-14
Primary completion
2025-11-01
Completion
2025-11-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Cannabidiol Other / unclassified 5 mg/kg Oral